Abstract
In 2008 the International Headache Society (IHS) published guidelines on “evaluation and registration of adverse events in clinical drug trials in migraine (Cephalalgia 2008; 28: 683-688). In this study we evaluated whether these guidelines on adverse events (AEs) subsequently were adhered to by reviewing , randomized, controlled trials (RCTs) on migraine drug treatment published in the three leading headache journals for the last 4 years.
Highlights
In 2008 the International Headache Society (IHS) published guidelines on “evaluation and registration of adverse events in clinical drug trials in migraine (Cephalalgia 2008; 28: 683-688)
In this study we evaluated whether these guidelines on adverse events (AEs) subsequently were adhered to by reviewing, randomized, controlled trials (RCTs) on migraine drug treatment published in the three leading headache journals for the last 4 years
We reviewed all double-blind RCTs on acute and preventive migraine drugs appearing in 2010, 2011, 2012, and 2013 in Headache, Journal of Headache and Pain, and Cephalalgia
Summary
Are the IHS’ recommendations for evaluation and registration of adverse events in drug trials in migraine being followed ?. From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark. From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark. 18-21 September 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
